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Dronedarone, a benzofuran containing chemical compound, is a derivative of amiodarone
which is classiﬁed as a Class III antiarrhythmic agent. It is prescribed to the cardiovas-
cular patients who have paroxysmal or persistent atrial ﬁbrillation to lower the chances of
hospitalization. Amiodarone, sotalol, procainamide dofetilide, quinidine, ibutilide, ﬂe-
cainide, and propafenone are the other useful medicinal products used to treat atrial
ﬁbrillation or cardiac arrhythmia. Dronedarone was approved for clinical use in atrial
ﬁbrillation by the Food and Drug Administration in 2009. The generic name for drone-
darone is Multaq (Sanoﬁ Aventis). This article brieﬂy highlights the important pharma-
cological, pharmacodynamic and pharmacokinetic properties of dronedarone.1. Introduction
Dronedarone is a structural analog of antiarrhythmic drug
amiodarone. It belongs to Class III of antiarrhythmic drugs.
Amiodarone is a popular antiarrhythmic agent but potential
toxicity associated with this drug limits its clinical usefulness. Its
regular use may cause several diseases such as thyroid disease,
pulmonary ﬁbrosis and also liver disease which might be due to
the presence of high iodine content in it. Dronedarone is rela-
tively a new drug which can lower the chances of hospitalization
in patients having cardiovascular diseases especially those with
paroxysmal or persistent atrial ﬁbrillation (AF), having sinus
rhythm (SR), or patients likely to be cardioverted[1]. It was given
approval for clinical use in AF by the Food and Drug
Administration in 2009.
AF is considered as one of the commonest forms of cardiac
arrhythmia. Some of the commonly associated risk factors forAF are heart failure, pericarditis, congential heart defects and
coronary artery disease, etc. The main therapeutic goals to be
achieved in the management of AF include: ventricular rate
control, prevention of thromboembolic events and rhythm con-
trol i.e., to restore the SR[2]. To control the ventricular rate, some
agents which typically block the atrioventricular node are used.
Commonly prescribed agents to control rate include calcium
channel blockers (diltiazem and verapamil), b-blockers and
digoxin, etc. Whereas, in rhythm control or restoration of SR,
Class Ic and III anti-arrhythmic agents are employed. The
currently available Class Ic and III are reported to have unpre-
dictable efﬁcacy and limiting safety proﬁle[3].
Multaq is a generic name for dronedarone marketed by a
multinational Sanoﬁ Aventis Company, Paris, France. Chemi-
cally, dronedarone is a non-iodine containing benzofuran analog
of antiarrhythmic drug amiodarone which is proven effective for
pharmacologic cardioversion[4,5]. In clinical trials, dronedarone
was found to be better than amiodarone in terms of having a
relatively quicker and short half-life, reduced lipophilicity, and
negligible non-cardiovascular toxicity. It is preferred for the long
term therapy of AF or ﬂutter in comparison to any other anti-
arrhythmic drug because of its safety and efﬁcacy. Dronedarone
has been proved to be quite safer and effective drug in con-
trolling the SR and decreasing the ventricular pro-arrhythmias.article under the CC BY-NC-ND license
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rhythm in AF patients having no record of heart disease, coro-
nary artery disease and hypertension without left ventricular
hypertrophy[6–9].
2. Chemistry
The chemical name of dronedarone is N-(2-Butyl-3-(p-(3-
(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methane-sul-
fonamide (Figure 1). Its molecular formula is C31H44N2O5S
with molecular mass of 556.758 g/mol.Figure 1. Chemical structure of dronedarone.Dronedarone is a benzofuran containing heterocyclic com-
pound and is a structural analog of amiodarone, but with slight
structural modiﬁcations where the iodine group is replaced by a
methane-sulfonyl group. The intention behind the replacement
of iodine group is to reduce the risk of non-target organ adverse
effects caused by amiodarone therapy. The substitution of iodine
with the methane-sulfonyl group reduces the lipophilicity and
thus decreases the risks of neurotoxicity and shortens the dro-
nedarone's half life signiﬁcantly[10–14]. Dronedarone is crystalline
in nature with melting point of 149–153 C. It also seems to
display activity in each of the 4 Vaughan-Williams
antiarrhythmic classes[15–17].
3. Pharmacology
3.1. Mechanism of action
Dronedarone is a Class III antiarrhythmic drug with charac-
teristics of all four Vaughan-Williams. Very similar to Class I
drugs, it shows rate-dependent inhibition of the rapid Na+ cur-
rent, inhibits a and b-adrenergic receptors like Class II agents,
exhibits blockade of K+ outward currents as the main mecha-
nism of action of Class III, and effectively block slow Ca2+
inward currents (Class IV)[18,19]. Class I and III effects provide an
insight into the mechanisms that induce rhythm control by
increasing refractory periods and decelerating cardiac
conduction. Because of its balanced inhibition of multiple
outward currents, it may reduce the transmural dispersion of
repolarization, that prevents signiﬁcant proarrhythmic effects
associated with other antiarrhythmic drugs[20]. Furthermore, in
comparison to pure potassium channel blockers, dronedarone
can increase duration of action potential and effective
refractory period without causing reverse use-dependency[20,21].
Beside this, Class II and IV effects of dronedarone can lead to
rate control properties along with anti-adrenergic (Class II)
and blood pressure lowering (Class IV) effects[22,23].
The electrophysiological effects of dronedarone in animal
models are found to be similar to the prototype drug,amiodarone. Similar to amiodarone prototype, oral dronedarone
also exhibits an increase in the PR interval in a dose-dependent
manner, as well as moderate prolongation of the QT interval
corrected for rate (QTc)[1,5,8]. Dronedarone also prolongs the RR
and QT intervals[14–17,24–26].
3.2. Indication
Dronedarone hydrochloride is used to lower the hospitaliza-
tion chances for cardiovascular events in patients with parox-
ysmal or persistent AF who have had a recent episode of
AF/atrial ﬂutter (AFL) and who have associated cardiovascular
risk factors (i.e., older than 70 years of age, hypertension, prior
cerebrovascular accident, diabetes, left atrial diameter of 50 mm
or greater, left ventricular ejection fraction of less than 40%).
The drug is indicated in patients who are in SR or who will
undergo cardioversion[24,25,27].
3.3. Posology
The maintenance dose is 1 tablet (400 mg) two times a day
i.e., morning and evening with meals. All antiarrhythmic drugs
of Class I, III and/or strong CYP3A4 inhibitors should be dis-
continued before initiating therapy with dronedarone.
3.4. Adverse events
Listed below are some of the common side effects of dro-
nedarone[1,24,28–31].
Use of dronedarone will lead to some gastrointestinal (GI)
effects including stomach pain, indigestion, nausea, vomiting,
heartburn, diarrhea, loss of appetite, loss of taste (rare), etc.
Some general side effects such as feeling of weakness or tired-
ness, loss of strength may also occur. Cardiac disfunctions such
as slow or irregular heart beats, bradycardia, heart failure (rare);
respiratory disorders including non-productive cough, difﬁculty
in breathing, interstitial lung disease; skin and subcutaneous
tissue side effects such as cracked, dry skin, itching skin, rashes
encrusted, scaly and oozing, eczema, dermatitis, redness or
discoloration of skin, photosensitivity reaction (rare) would also
appear during dronedarone usage (Table 1).
Laboratory data/electrocardiograph parameter changes
including increased serum creatinine, bilirubin and hepatic en-
zymes, QTc prolongation (28%) can also occur.
3.5. Overdose
The overdose of dronedarone can be very toxic. It is not
known whether dialysis (hemodialysis, peritoneal dialysis, or
hemoﬁltration) can remove dronedarone and/or its metabolites
from the blood. Currently, speciﬁc antidote is not available for
the dronedarone toxicity either due to accidental or intentional
overdosing. In case of overdose, supportive treatment is pro-
vided which aimed towards alleviating symptoms.
3.6. Contraindications
Dronedarone is contraindicated in the following condi-
tions[10,25,32]: (a) atrio-ventricular block (2nd or 3rd degree), sick
sinus syndrome (except when used together with well opera-
tional pacemaker); (b) bradycardia with less than ﬁfty beats per
Table 1
Some common side effects of dronedarone.
Frequency Side effects
Very common ( 1/10) Cardiac disorders: Congestive heart failure and QT interval prolonged.
Blood creatinine increased
Common ( 1/100 to < 1/10) Asthma, fatigue, rashes, liver function abnormalities, diarrheas, vomiting
nausea, abdominal pain, dyspepsia
Rare ( 1/10000 to < 1/1000) Anaphylactic reactions including angioedema, ageusia, leukocytoclastic
vasculitis, hepatocellular liver injury including life-threatening acute liver
failure.
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inhibitors e.g. azithromycin, telithromycin, clarithromycin,
erythromycin, cobicistat, chloramphenicol, clotrimazole,
cyclosporine, cimetidine, diltiazem, ﬂuoxetine, ﬂuconazole,
ketoconazole, miconazole, oxiconazole, itraconazole, pos-
aconazole, voriconazole, ﬂuvoaxamine, gestodene, indinavir,
nelﬁnavir, ritonavir, saquinavir, ritonavir, valproic acid, etc.;
(d) patients who are using herbal products and other drugs
which increase the QT interval and drugs like tricyclic anti-
depressants, bepridil, cisapride, phenothiazines, terfenadine
and some oral macrolide which might induce Torsades de
Pointes; (e) patients with the highest QTc Bazett interval
( 500 ms); (f) pregnancy and lactating women; (g) patients
with unstable hemodynamic conditions; (h) patients with a
history of left ventricular systolic dysfunction or having a heart
failure; (i) patients who reported to have lung and liver toxicity
due to use of amiodarone; (j) severe case of liver dysfunction or
any type of hepatic toxicity; (k) kidney dysfunction or any type
of severe renal impairment with low creatinine clearance
(CrCl < 30 mL/min).
3.7. Warnings and precautions
Severe liver injury as well as acute liver failure was observed
in dronedarone (Multaq) treated patients in the post-marketing
surveillance[32,33].
There is a strong possibility of hypomagnesemia or hypo-
kalemia with concurrent use of potassium-depleting diuretics
with dronedarone. We should ascertain that level of serum
magnesium and potassium concentrations are within normal
limits before initiating the therapy and maintained within normal
range during the duration of the therapy of dronedarone[32,33].
3.8. Drug interaction
Dronedarone interacts with many drugs (so need to avoid
concurrent use) such as antiarrhythmic drugs, digoxin (we
should discontinue or divide the dose of digoxin and monitor
during the treatment), beta-blockers, calcium channel blockers,
HMG-CoA reductase inhibitors, monoamine oxidase inhibitors,
lactose, juice of grapefruit, CYP3A substrates with low thera-
peutic index like tacrolimus and sirolimus, and CYP3A inducers
viz. carbamazepine, phenytoin, phenobarbital, rifampicin, potent
CYP3A4 inhibitors like azithromycin, telithromycin, clari-
thromycin, erythromycin, cobicistat, chloramphenicol, clotri-
mazole, cyclosporine, cimetidine, diltiazem, ﬂuoxetine,
ﬂuconazole, ketoconazole, miconazole, oxiconazole, itracona-
zole, posaconazole, voriconazole, ﬂuvoxamine, gestodene, in-
dinavir, nelﬁnavir, ritonavir, saquinavir, ritonavir, valproic acid,
etc.[24–26,34,35].4. Pharmacokinetics and pharmacodynamics
4.1. Pharmacodynamic properties
Dronedarone decreases the heart rate and increases the
Wenckebach cycle length and AH-, PQ-, QT-intervals. It has no
noticeable effect but weakly amplify the QTc-intervals, further,
it does not change HV- and QRS intervals. It also augments the
effective refractory periods of the atrium, atrio-ventricular node,
while cause little prolongation in the ventricular effective re-
fractory periods[1,10].
Dronedarone decreases myocardial oxygen consumption,
reduces arterial blood pressure and contractility of myocardium
with no effect in left ventricular output volume.
It has vaso-dilatory properties and also been reported to show
indirect anti-adrenergic effects with partial antagonism of stim-
ulation of adrenergic system.
4.2. Pharmacokinetic properties
Dronedarone is less lipophilic as compared to the amiodar-
one. It has very less volume of distribution. The elimination
half-life (t1/2) of dronedarone is quite shorter (13–19 h) in
contrast to half-life of amiodarone which is several weeks. The
dose of dronedarone may be less complex than amiodarone due
to the pharmacokinetic proﬁle[14,36–38] (Table 2).
4.2.1. Absorption
The absorption is nearly 70%–94% which increases signiﬁ-
cantly in presence of food. The bioavailability (absolute) in
absence of food is reported as low which is nearly 4% and this is
mainly due to pre-systemic ﬁrst pass metabolism. The presence
of fatty meal increases the bioavailability of dronedarone to
nearly about 15%, therefore, it is recommended to be taken with
food. Tmax of dronedarone and its active metabolite N-debutyl is
reported as 3–6 h and steady-state concentrations are achieved in
4–8 days upon oral administration after meal. When dronedar-
one is administered repeatedly in a dose of 400 mg twice daily, it
shows mean accumulation ratio from 2.6 to 4.5. The maximal
steady-state concentration is found to be 84–167 ng/mL. The
area under the curve is 650–1030 ng$h/mL. The steady state
Cmax and contact of its active metabolite of N-debutyl is reported
to be similar. The pharmacokinetic properties of both drone-
darone and its metabolite “N-debutyl”’ show a slight deviation
from the dose proportionality: doubling the dose results in nearly
2.5–3.0 times increase in Cmax and area under the curve[14,49].
4.2.2. Distribution
Dronedarone and its main active metabolite N-debutyl binds
strongly to the plasma proteins (> 98%), mostly to the albumin
Table 2
Comparison of amiodarone and dronedarone[39–45].
Drug Vaughan Williams Indication Onset of
action
Half life Protein binding
and metabolism
Route of
elimination
Dronedarone All four classes of
Vaughan Williams
To decrease the chances of
hospitalization in case of sudden/
continual AF/AFL with current
episode of AF/AFL & related CV
risk factors[41].
4–8 h 13–19 h > 98% by CYP3A
and CYP2D6[47]
~ renal (6%) and
feces (84%)[48]
Amiodarone All I–IV classes, but
predominantly
Class III
Paroxysmal supra-ventricular
tachycardia (paroxysmal SVT);
Recurrent ventricular ﬁbrillation;
Supra-ventricular arrhythmias;
Unstable ventricular tachycardia;
Recurrent supra-ventricular
tachycardia; Management of acute
AF and long term treatment to
prevent recurrence of AF[46]
Few days to
weeks (1–3)
40–55
days
> 96%, by CYP3A4
and CYP2C8[38]
Metabolized by
liver & biliary
excretion[24]
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ranges from 1200 to 1400 L after intravenous administration.
Dronedarone is widely distributed in kidneys, liver, lungs,
myocardium and also crosses the blood-brain and placental
barriers[48].
4.2.3. Biotransformation
Dronedarone is metabolized by the cytochrome (CYP) P450
CYP3A4 isoenzyme (> 84%) to its active metabolite N-debutyl
and the inactive propanoic acid metabolite. Its active metabolite
is 3–10 folds less potent than dronedarone. The initial metabolic
pathway involves N-debutylation which results in the formation
of an active N-debutyl metabolite. The active metabolite further
undergoes oxidative deamination and direct oxidation to form an
inactive propionic acid metabolite. The metabolite through a
series of biotransformation also yields more than 30 unidentiﬁed
metabolites. The main active metabolite N-debutyl possesses
1/10 to 1/3 pharmacodynamic activity in comparison to parent
drug[46,50].
4.2.4. Elimination
The elimination half-life of dronedarone varies from 13 to
19 h. It is mainly excreted in the feces (84%), while 6% is
excreted in the urine. It is reported in the mass balance study of
dronedarone that orally administered dronedarone (14C-labeled)
approximately 6% and 84% of the labeled dose was excreted in
urine and in faeces respectively, chieﬂy as active metabolites.
This drug is not excreted in urine as unchanged compound.
Dronedarone and its active metabolite N-debutyl dronedarone is
reported to be fewer than 15% of the resultant radioactivity in
the plasma. The plasma clearance (Cl) of dronedarone is
approximately 130–150 L/h after IV administration[47].
4.2.5. Special populations
There is no difference in the pharmacokinetic proﬁle of
dronedarone among healthy subjects and AF patients[14]. The
female patients have shown higher plasma exposure of
dronedarone as compared with male patients. The plasma
exposure of dronedarone is approximate1y 1.3-fold greater in
females as compared to their counterparts. With respect to the
body weight, the plasma exposure of drug is 1.4 times higher
among the patients having body weight 60 kg in comparison to
the patients with 60–100 kg of body weight. The pharmacoki-
netics of dronedarone does not differ signiﬁcantly amongpatients having heart failure and kidney diseases history. The
dosage adjustment is not required in the patients having mod-
erate liver dysfunction. Dronedarone is contraindicated in the
patients suffering from severe hepatic impairment since severe
hepatocellular liver damage and sometime life-threatening acute
liver failure has been reported in patients treated with drone-
darone in the post-marketing surveillance studies. In patients
suffering from moderate hepatic impairment, it was observed
that the steady-state exposure increased by 1.3-folds for drone-
darone and decreased from 1.6 to 1.9-folds for its active
metabolite[32].
5. Preclinical safety data
In preclinical safety study of dronedarone, it is reported that
dronedarone had no genotoxic property after evaluation of four
in vitro tests and in vivo micronucleus test in mice[6,12,28–30,51–54].
5.1. ATHENA
In ATHENA study, Connolly et al. conducted a placebo
controlled, double blind trial[6].
They included total 4628 patients with age over 75 years in
the study. All patients were checked if they had either persistent
or paroxysmal AF or AFL and at least one added risk factor for
cardiovascular events. These patients were randomly received
either placebo or dronedarone 400 mg twice daily. All these
patients were treated for the duration of minimum twelve
months. In this study, the primary end point was death due to
any cause or cardiovascular hospitalization, while secondary end
points were cardiovascular hospitalization or cardiovascular
death.
There was a statistically signiﬁcant reduction in the drone-
darone group for cardiovascular death, total strokes, transient
ischemic attack, and the composite of stroke.
5.2. EURIDIS and ADONIS
A double blind, randomized trial was conducted by Singh
et al., total 828 patients included[55]. These patients were
randomized to receive either placebo or dronedarone 400 mg
two times daily. In this study, a primary end point was time
to recurrence of AF, while secondary end points were
symptoms associated with AF and the mean ventricular rate
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decreased and QT interval was prolonged in the dronedarone
treated group.
5.3. DAFNE
A double-blind, randomized placebo-controlled, dose-
ranging study of the dronedarone was carried out for the pre-
vention of AF[28]. This study used three different doses of
dronedarone viz. 400 mg, 600 mg, and 800 mg, two times
daily in 270 patients with AF contrast to placebo for the
management of SR following electrical cardioversion. The
treatment was continued for the duration of 6 months. The
dronedarone at a dose of 400 mg twice daily as compared to
placebo delayed the AF recurrence. This study demonstrated
that dronedarone at a dose of 400 mg orally twice daily
regimen had more efﬁcacy and it was considered to be
adequately safe to continue to more clinical trials.
5.4. ERATO
A double-blind, randomized, placebo-controlled trial was
carried out to evaluate the efﬁcacy and safety of dronedarone for
the control of ventricular rate during AF (ERATO)[30]. A total of
174 patients with symptomatic permanent AF were included in
the study. The efﬁcacy of dronedarone 400 mg two times
daily for the duration of 6 months in controlling ventricular
rate in these patients was evaluated. It was noted that
dronedarone signiﬁcantly decreased the ventricular rate and
this effect was sustained during the course of study i.e., six
months.
5.5. ANDROMEDA
The evaluation of dronedarone in moderate-to-severe conges-
tive heart failure for morbidity decrease (ANDROMEDA) is a
randomized double-blind, placebo-controlled trial based study in
627 patients hospitalized for heart failure[56]. The study was carried
out for the evaluation of the efﬁcacy of dronedarone at a dose of
400 mg two times daily on the risk of hospitalizations for
worsening heart failure or mortality.
It was observed that only one fourth of the study population
had atrial ﬂutter/AF at randomization. There was a total of ten
deaths due to worsening heart failure in the dronedarone treated
group while only two deaths were seen in the placebo group.
The trial was early terminated due to this outcome and obser-
vations. The exact mechanism which leads to worsening of heart
failure in dronedarone treated group is unknown and need to be
investigated. One of the possible mechanisms of this toxicity
which was caused by increase in the serum creatinine level could
be due to the withdrawal of angiotensin-converting enzyme in-
hibitors in dronedarone patients.
6. Conclusions
The dronedarone has been observed to be more efﬁcacious in
reducing the incidence of recurrence of AF. The dronedarone is
also found to be better tolerated than amiodarone. It is shown to
have a low pro-arrhythmic risk and this is the ﬁrst anti-
arrhythmic drug which has been found to reduce risk factor
for recurrent AF, cardiovascular mortality and hospitalization inpatients who are clinically stable along. Therefore, dronedarone
as an anti-arrhythmic drug, has been recommended as drug of
choice for the maintenance of SR in the clinically stable patients.
Many studies have also proved that dronedarone is a potent anti-
arrhythmic drug.
In the ADONIS and EURIDIS studies, the efﬁcacy of dro-
nedarone in maintaining SR was evaluated. The dronedarone
signiﬁcantly reduced the risk of recurrence of AF as compared to
placebo. The capacity of dronedarone to control ventricular rate
in permanent AF was evaluated in the ERATO study. The re-
currences of AF were demonstrated in the DIONYSOS study.
Additionally, it was also demonstrated in the ATHENA study
that dronedarone can greatly reduce the death and cardiovascular
hospitalization (24%) in patients due to SR. On the other hand,
the efﬁcacy of dronedarone in patients with recent decom-
pensated heart failure was also evaluated in the ANDROMEDA
study. The use of dronedarone in patients with chronic AF was
evaluated in the PALLAS. These studies were permanently
terminated due to a tendency of higher risk of cardiovascular
events.
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